IO-202

· Immune-Onc Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for IO-202, covering 2024-06-04 to 2025-02-14. Get the full timeline:

Most recent: Clinical Trial Update: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML [Phase 1]